UToledo Health Now Offering FDA-Approved Infusion Therapy to Help Slow Early Alzheimer’s Progression

UToledo Health Now Offering FDA-Approved Infusion Therapy to Help Slow Early Alzheimer's Progression

While Alzheimer's disease cannot be reversed, new treatment options are offering patients and families something meaningful: more time.

UToledo Health is now offering Kisunla, an FDA-approved infusion therapy designed to slow the progression of early symptomatic Alzheimer's disease. The treatment targets amyloid plaques in the brain associated with the disease, with the goal of early intervention reducing plaque buildup over time and helping patients maintain their independence longer.

"The focus of Alzheimer's disease treatment has shifted from short-term cognitive improvement to slowing disease progression particularly in early stages and that is also the aim of the monoclonal antibodies novelty treatments," said Dr. Alina Rais, a UToledo Health psychiatrist.

Kisunla is administered via IV infusion once every four weeks, with each session typically lasting about 30 minutes. Before treatment begins, imaging is required to evaluate eligibility and monitor safety throughout the course of care. UToledo Health's care team will determine the appropriate number of infusions based on each patient's individual needs.

The therapy is available to patients with a confirmed diagnosis of early symptomatic Alzheimer's disease. A referral is not required, but eligibility is determined through an individual clinical evaluation during an appointment scheduled by the patient. Kisunla is not appropriate for all patients, and the UToledo Health care team will review potential risks and side effects with each patient prior to beginning treatment.

Infusion therapy is covered by insurance, though prior authorization is required. UToledo Health staff will help patients verify their benefits.

To schedule an evaluation or learn more, contact UToledo Health at 419.383.5695 option 2, or email [email protected].